Cargando…
Pulmonary delivery of mucosal nanovaccines
Mucosal vaccination can elicit both systemic and mucosal immunity, and therefore has the potential to not only treat mucosal immune diseases, prevent the pathogen infection at the mucosal entry sites, but also treat distant or systemic immune disorders. However, only a few mucosal vaccines have been...
Autores principales: | Tang, Wei, Zhang, Yu, Zhu, Guizhi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Royal Society of Chemistry
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734613/ https://www.ncbi.nlm.nih.gov/pubmed/34918733 http://dx.doi.org/10.1039/d1nr06512b |
Ejemplares similares
-
Mucosal delivery of nanovaccine strategy against COVID-19 and its variants
por: Lee, Junwoo, et al.
Publicado: (2023) -
Virus-Like Particles-Based Mucosal Nanovaccines
por: Rosales-Mendoza, Sergio, et al.
Publicado: (2019) -
Recent progress in application of nanovaccines for enhancing mucosal immune responses
por: Du, Guangsheng, et al.
Publicado: (2023) -
Responsive Multivesicular Polymeric Nanovaccines that Codeliver STING Agonists and Neoantigens for Combination Tumor Immunotherapy
por: Su, Ting, et al.
Publicado: (2022) -
A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer
por: Ni, Qianqian, et al.
Publicado: (2020)